Alnylam Pharmaceuticals (ALNY) net income: $314M
Alnylam Pharmaceuticals reported a net income of $314M for the year ended Dec 31, 2025.
From Alnylam Pharmaceuticals's filings with the SEC · Read the filing · ALNY stock page
Alnylam Pharmaceuticals net income by year
#784 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | $314M | – |
| Dec 31, 2024 | −$278M | – |
| Dec 31, 2023 | −$440M | – |
| Dec 31, 2022 | −$1.1B | – |
| Dec 31, 2021 | −$853M | – |
Net income of similar companies
Companies in the same industry as Alnylam Pharmaceuticals, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Acadia Pharmaceuticals | $391M | Dec 31, 2025 |
| Rigel Pharmaceuticals | $367M | Dec 31, 2025 |
| Biomarin Pharmaceutical | $349M | Dec 31, 2025 |
| Alnylam Pharmaceuticals | $314M | Dec 31, 2025 |
| Aurinia Pharmaceuticals | $287M | Dec 31, 2025 |
| BeOne Medicines | $287M | Dec 31, 2025 |
| Alkermes | $242M | Dec 31, 2025 |
Questions and answers
What is Alnylam Pharmaceuticals's net income?
Alnylam Pharmaceuticals reported a net income of $314M for the year ended Dec 31, 2025.
Numbers as reported in Alnylam Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology